Records 1 - 11 (of 11 Records)
|Query Trace: Diarrhea and UGT1A[original query]|
| Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 May 24 (15): 2237-44.
Han Ji-Youn, Lim Hyeong-Seok, Shin Eun Soon, Yoo Yeon-Kyeong, Park Yong Hoon, Lee Jong-Eun, Jang In-Jin, Lee Dae Ho, Lee Jin S
| Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Clinical colorectal cancer 2007 Jul 6 (8): 583-7.
Fakih Marwan G, Ross Mary Ellen, Starostik Pe
| [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Zhonghua zhong liu za zhi [Chinese journal of oncology] 2007 Dec 29 (12): 913-6.
Wang Yan, Xu Jian-Ming, Shen Lin, Xu Nong, Wang Jin-Wan, Jiao Shun-Chang, Zhang Jing-Sheng, Song San-Tai, Li Jian, Bao Han-Ying, Yang Lin, Li Fa
| Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Apr 22 (4): 890-6.
Park S R, Kong S-Y, Rhee J, Park Y-I, Ryu K W, Lee J H, Kim Y-W, Choi I J, Kim C G, Lee J Y, Cho S-J, Kim N
| The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
Cancer chemotherapy and pharmacology 2012 Jun 69 (6): 1591-9.
Lamas M J, Duran G, Balboa E, Bernardez B, Candamio S, Vidal Y, Mosquera A, Giraldez J M, Lopez R, Carracedo A, Barros
| Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
The Tohoku journal of experimental medicine 2013 229 (2): 107-14.
Inoue Kazuyuki, Sonobe Momoyo, Kawamura Yukinori, Etoh Takashi, Takagi Masakazu, Matsumura Takashi, Kikuyama Masataka, Kimura Midori, Minami Sato, Utsuki Hiroaki, Yamazaki Tomoaki, Suzuki Takayo, Tsuji Daiki, Hayashi Hideki, Itoh Kunihi
| Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
Thoracic cancer 2017 Jan 8 (1): 40-45.
Fukuda Minoru, Shimada Midori, Kitazaki Takeshi, Nagashima Seiji, Hashiguchi Kohji, Ebi Noriyuki, Takayama Koichi, Nakanishi Yoichi, Semba Hiroshi, Harada Taishi, Seto Takashi, Okamoto Isamu, Ichinose Yukito, Sugio Ken
| Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
BMC cancer 2017 Jun 17 (1): 437.
Liu Dan, Li Jian, Gao Jing, Li Yanyan, Yang Rui, Shen L
| UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
Cancer chemotherapy and pharmacology 2017 Jun 79 (6): 1109-1117.
Chen Xuewei, Liu Liping, Guo Zhihua, Liang Wenhua, He Jiaxi, Huang Liyan, Deng Qiuhua, Tang Hailing, Pan Hui, Guo Minzhang, Liu Yang, He Qihua, He Jianxi
| Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism.
Case reports in oncological medicine 2017 11 2017 2683478.
Jannin Arnaud, Hennart Benjamin, Adenis Antoine, Chauffert Bruno, Penel Nicol
| The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients.
Genomics & informatics 2022 Sep 20 (3): e29.
Lee Choong-Kun, Chon Hong Jae, Kwon Woo Sun, Ban Hyo-Jeong, Kim Sang Cheol, Kim Hyunwook, Jeung Hei-Cheul, Chung Jimyung, Rha Sun You
- Page last reviewed:Oct 1, 2023
- Page last updated:Nov 28, 2023
- Content source: